Overview

Practice Solutions for Addressing Treatment Delays in Black Patients With Metastatic Castration Resistant Prostate Cancer

Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.

Start Activity

Format

Interactive Practice Guide

Time to Complete

1.25 hr(s).

Release Date

July 15, 2025

Expires On

July 15, 2026

Outcomes studies have shown that Black men are 70% more likely to develop prostate cancer, have earlier onset and more aggressive disease, and higher rates of morbidity and mortality compared to White men. But recent studies have found that after adjusting for nonbiological factors such as access to care and standardized treatment, Black men with metastatic disease realize more favorable survival benefits when provided equal access to therapy.

While Black men have been underrepresented in clinical trials and less likely to undergo genomic profiling of metastatic prostate cancer, a key opportunity lies with facilitating access to novel therapies, especially for heavily pre-treated patients with metastatic castration resistant prostate cancer (mCRPC). Studies show that Black men diagnosed with more advanced stages of prostate cancer are significantly less likely to be prescribed novel hormone therapy than other racial and ethnic groups.

When considering that the growing number of therapeutic options for prostate cancer already creates challenges for navigating optimal treatment selection and sequencing, finding solutions to mitigate access to novel agents further challenges the implementation of evidence-based medicine into real-world practice. In response, this educational activity has compiled education and practical tools to help you efficiently and effectively bridge these gaps. It also includes downloadable slide decks and discussion guides to initiate meaningful conversations and improve interprofessional care within your team. Drive changes to positively impact care for your patients by ensuring all patients have access to the right therapies at the right time.

This program is intended for medical oncologists, urologists, pathologists, nurse practitioners, physician assistants, oncology pharmacists, nurse navigators and other members of the multidisciplinary team who care for patients with prostate cancer.

Prostate cancer is the second leading cause of death from cancer in men in the United States. Outcomes are worse for Black men who are 70% more likely to develop prostate cancer, twice as likely to die from the disease, and for whom advanced metastatic prostate cancer occurs at a 4:1 ratio compared to white men of European ancestry. Current evidence suggests that there is a significant gap in treatment rates between Black and white men. Studies show that African American and Hispanic men have significant disparity in the receipt of definitive therapy compared to Caucasian men, and higher tumor grade was associated with decreasing odds of definitive therapy for these populations. While the etiology for these racial differences in the clinical behavior of prostate cancer is largely unknown, hormonal, nutritional, genetic, behavioral, and socioeconomic factors have all been implicated. Providers must be aware of disparities faced by specific patient population and implement processes to routinely assess needs and barriers across the disease course, providers, and healthcare systems.

Upon completion of this activity, learners will be able to:
• Introduce strategies to reduce the median time to treatment for diverse patients with mCRPC
• Optimally select targeted therapies in the advanced prostate cancer setting considerate of patient- and disease-related factors
• Identify patients with mCRPC who may be eligible for a clinical trial
• Apply tactics to improve care coordination, access to care, and SDM for Black men with mCRPC

Pharmacy Learning Objectives
Upon completion of this activity, pharmacists will be able to:
• Introduce strategies to reduce the median time to treatment for diverse patients with mCRPC
• Optimally select targeted therapies in the advanced prostate cancer setting considerate of patient- and disease-related factors
• Apply tactics to improve care coordination, access to care, and SDM for Black men with mCRPC

Didactic Modules
Overview of Inequities in Prostate Care
Treatment of mCRPC
Optimizing Treatment Strategies for Black Men
Supportive Care
Personalized and Precision Medicine for mCRPC

Case-based Discussion

Case Study: 67-year-old man with advanced prostate cancer and gaps in care

Case Study: 68-year-old man requiring therapy for rising PSA and new bone metastases

Provided by University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL).

This is supported by educational grants from Astellas and Pfizer Inc., Bayer HealthCare Pharmaceuticals Inc, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Russell Z. Szmulewitz, MD (Chair)
Professor of Medicine
Director, Genitourinary Oncology Program
Associate Director for Clinical Investigation, Comprehensive Cancer Center
Co-Director, High Risk and Advanced Prostate Cancer Clinic
University of Chicago
Chicago, IL

Samuel L. Washington III, MD, MAS (Faculty)

Assistant Professor, Urology

Urologic Oncologist

University of California, San Francisco

San Francisco, CA

Meghan Catenacci, BSN, RN, MS (Faculty)

Oncology Nurse Navigator

Hematology/Oncology

University of Chicago Medicine

Chicago, IL

Timothy McNichol, LCSW (Faculty)

Genitourinary Outpatient Social Worker

Medical Oncology

University of Chicago Medicine

Chicago, IL

Rebecca LaRue, PharmD, BCOP (Pharmacy Planner)

Clinical Pharmacy Specialist Hematology/Oncology/Cellular Therapy

Team Lead Hematology/Oncology Pharmacy

Rush University Medical Center

Chicago, IL

As providers accredited by the ACCME, The University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL) ask everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine and ACHL require authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.

The following financial relationships have been provided:
Russell Z. Szmulewitz, MD
Advisor: Bayer, Novartis, Pfizer, Johnson & Johnson
Research Funding (Institution): Abbvie, Bayer, Janus, Merck, Novartis, Nurix, Pfizer

Samuel L. Washington III, MD, MAS
No financial relationships to disclose.

Meghan Catenacci, BSN, RN, MS
Consultant: Novartis

Timothy McNichol, LCSW
No financial relationships to disclose.

Rebecca LaRue, PharmD, BCOP
No financial relationships to disclose.

The University of Chicago Pritzker School of Medicine, ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of any publisher or grantor(s).

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL and The University of Chicago requires the speaker to disclose that a product is not labeled for the use under discussion.

Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: None

This activity will take approximately 75 minutes to complete. To receive credit, learners are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

Partial credit may not be awarded for CPE credit; participation in the complete activity is required to receive credit. CPE credit will be submitted to CPE Monitor® on the first business day of each month.

The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

By providing your ABIM Diplomate number, you consent to have ACHL and/or our educational partners submit your participation in this activity to the ABIM through the ACCME PARS system. ABIM credit will be submitted to PARS on the first day of each month.

Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This activity has been approved for 1.25 contact hours.

ACPE Universal Activity Number: 0396-9999-25-017-H01-P
Activity Type: Application
Release Date: July 15, 2025
Expiration Date: July 15, 2026

Laurie Novoryta
lnovoryta@achlcme.org

Overview

Practice Solutions for Addressing Treatment Delays in Black Patients With Metastatic Castration Resistant Prostate Cancer

Program Description

Intended Audience

Activity Purpose

Learning Objectives

Meeting Schedule

Provider Information

Supporter Information

Faculty

Faculty Disclosure

Staff Disclosure

Disclaimer

Method of Participation

Accreditation and Credit Designation

Program Manager

Related Activities